Calcimimetics versus parathyroidectomy: What is preferable?
Secondary hyperparathyroidism (SHPT) is common among patients with end-stage renal disease (ESRD). SHPT is associated with high-turnover bone disease, interstitial and vascular calcifications, cardiovascular morbidity and mortality. The pharmacological management of SHPT has progressed in recent years. The introduction of targeted therapies, such as selective vitamin D receptors activators and calcium-sensing receptor modulators, offers an increased opportunity to adequately control elevated parathyroid hormone (PTH), especially in patients with chronic kidney disease under dialysis treatment. Calcimimetic medications such as cinacalcet negatively feedback on the parathyroid glands and do not have the consequences of calcium augmentation. However, there are no randomised, prospective data that demonstrate improved quality of life, improvement in anemia, reduction in phosphate binders, reduction in use of vitamin D analogs, or reduction in mortality. Literature supports cinacalcet therapy to improve patient outcomes, especially with regard to vascular calcifications and presumably the very lethal condition of calciphylaxis. However, cinacalcet is administered orally and has been associated with gastrointestinal intolerance along with hypocalcemia. In addition, poor adherence has been observed among dialysis patients self-administering oral cinacalcet. On the other hand, successful surgical parathyroidectomy (sPTX) can yield a dramatic reduction in PTH level and clinical symptoms. The advanced pharmacological treatments of SHPT often obviate parathyroidectomy; however, some researchers have reported that sPTX may be more cost-effective than cinacalcet in some patients with ESRD and suffering uncontrolled SHPT.
KeywordsDialysis Secondary hyperparathyroidism Parathyroidectomy Calcimimetic
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 1.Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Kidney disease: improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953CrossRefPubMedGoogle Scholar
- 2.Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J, Osteoporosis Work Group (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566–571CrossRefPubMedGoogle Scholar
- 6.KDIGO (2012) Clinical practice guideline for the evaluation and management of chronic kidney disease, vol 3(1), pp 1–150, January 2013Google Scholar
- 8.National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1Google Scholar
- 14.Arenas MD, Alvarez-Ude F, Gil MT et al (2007) Implementation of ‘K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease’ after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transpl 22(6):1639–1644CrossRefGoogle Scholar
- 15.Fishbane S, Shapiro WB, Corry DB et al (2008) Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 3(6):1718–1725CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Locatelli F, Messa P, Bellasi A et al (2013) What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results. G Ital Nefrol 30(5):pii:gin/30.5.4Google Scholar
- 25.Wheeler DC et al (2014) Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. J Am Heart Assoc 3(6):e001363. https://doi.org/10.1161/jaha.114.001363 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Goldsmith D, Covic A, Vervloet M, Cozzolino M, Nistor I (2015) Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board; should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transpl 30(5):698–700CrossRefGoogle Scholar
- 34.Fassbinder W, Brunner FP et al (1991) Combined report on regular dialysis and transplantation in Europe. Nephrol Dial Transpl 6(Suppl 1):5–35Google Scholar
- 36.Esposito MG, Cesare CM, De Santo RM et al (2008) Parathyroidectomy improves the quality of sleep in maintenance hemodialysis patients with severe hyperparathyroidism. J Nephrol Suppl 13:S92–S96Google Scholar
- 50.Conzo G, Perna A, Savica S et al (2013) Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to calcimimetics era. BMC Surg 13(Suppl 2):S4. https://doi.org/10.1186/1471-2482-13-s2-s4 CrossRefPubMedPubMedCentralGoogle Scholar
- 52.van der Plas WY, Dulfer RR, Engelsman AF et al (2017) Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transpl 32(11):1902–1908Google Scholar